Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes

Molecular Therapy

Volumn 9, Issue 4, 2004, Pages 577-586

  Wang, Jinjuan ^a   Press, Oliver W ^a,b,c   Lindgren, Catherine G ^c   Greenberg, Philip ^a,b   Riddell, Stanley ^a,b   Qian, Xiaojun ^a   Laugen, Christian ^a   Raubitschek, Andrew ^d   Forman, Stephen J ^d   Jensen, Michael C ^d  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

CD20; Cellular immunotherapy; CTL clones; Follicular lymphoma; scFvFc: chimeric TCR

Indexed keywords

ANTIBIOTIC G 418; CD20 ANTIBODY; CD20 ANTIGEN; CD8 ANTIGEN; KANAMYCIN KINASE; OKT 3; RECOMBINANT INTERLEUKIN 2; T LYMPHOCYTE RECEPTOR;

ANTIGEN SPECIFICITY; ARTICLE; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CELL ISOLATION; CELL SELECTION; CELLULAR IMMUNITY; CHIMERA; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DILUTION; DNA MODIFICATION; ELECTROPORATION; FEASIBILITY STUDY; FOLLICULAR LYMPHOMA; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; LYMPHATIC LEUKEMIA; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CLONE; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; MOLECULAR CLONING; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMID; SPLEEN TUMOR; TUMOR CELL DESTRUCTION;

EID: 2342655822     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2003.12.011     Document Type: Article

References (37)

1. Glass, A. G., Karnell, L. H., and Menck, H. R. (1997). The national cancer database report on non-Hodgkin's lymphoma. Cancer 80: 2311-2320.
2. Press, O. W., et al. (1987). Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B-cell lymphomas. Blood 69: 584-591.
3. Press, O. W., et al. (1993). Radiolabeled-antibody therapy of B lymphoma with autologous bone marrow support. N. Engl. J. Med. 329: 1219-1224.
4. Maloney, D. G., et al. (1997). IDEC-C2B8: Results of a Phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J. Clin. Oncol. 15: 3266-3274.
5. Maloney, D. G., et al. (1997). IDEC-C2B8: (Rituximab) Anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90: 2188-2195.
6. McLaughlin, P. (2001). Rituximab: perspective on single agent experience, and future directions in combination trials. Crit. Rev. Oncol. Hematol. 40: 3-16.
7. Mclaughlin, P., et al. (1998). Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16: 2825-2833.
8. Piro, L. D., et al. (1999). Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol. 10: 655-661.
9. Foran, J. M., et al. (2000). A UK multicentre Phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. Br. J. Haematol. 109: 81-88.
10. Davis, T. A., et al. (1999). Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a Phase II trial of rituximab. J. Clin. Oncol. 17: 1851-1857.
11. Czuczman, M. S., et al. (1999). Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J. Clin. Oncol. 17: 268-276.
12. Countouriotis, A., Moore, T. B., and Sakamoto, K. M. (2002). Cell surface antigen and molecular targeting in the treatment of hemotologic malignancies. Stem Cells 20: 215-229.
13. Ho, W. Y., Blattman, J. N., Dossett, M. L., Yee, C., and Greenberg, P. D. (2003). Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell 3: 431-437.
14. + T cells: it may get by a little help from its friends. J. Clin. Invest. 110: 1415-1417.
15. Kalos, M. (2003). Tumor antigen-specific T cells and cancer immunotherapy: current issues and future prospects. Vaccine 21: 781-786.
16. Knutson, K. L., Almand, B., Mankoff, D. A., Schiffman, K., and Disis, M. L. (2002). Adoptive T cell therapy for the treatment of solid tumors. Expert Opin. Biol. Ther. 2: 55-66.
17. Dudley, M. E., et al. (2002). Cancer regression and autoimmunity in patients after clonal repopulation with anti-tumor lymphocytes. Science 298: 850-854.
18. Rooney, C. M., et al. (1998). Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92: 1549-1555.
19. Roskrow, M. A., et al. (1998). Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood 91: 2925-2934.
20. Heslop, H. E., et al. (1996). Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat. Med. 2: 551-555.
21. Peggs, K. S., and Mackinnon, S. (2002). Clinical trials with CMV-specific T cells. Cytotherapy 4: 21-28.
22. Walter, E. A., et al. (1995). Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T cell clones from the donor. N. Engl. J. Med. 333: 1038-1044.
23. Riddell, S. R., Watanabe, K. S., Goodrich, J. M., Li, C. R., Agha, M. E., and Greenberg, P. D. (1992). Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257: 238-241.
24. + T cell clones for the treatment of patient with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA 99: 16168-16173.
25. Gross, G., and Eshhar, Z. (1992). Endowing T cells with antibody specificity using chimeric T cell receptors. FASEB J. 6: 3370-3378.
26. Eshhar, Z., et al. (1993). Specific activation and targeting of cytotoxicity lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T cell receptors. Proc. Natl. Acad. Sci. USA 90: 720-724.
27. Stancovski, I., Schindler, D. G., Waks, T., Yarden, Y., Sela, M., and Eshhar, Z. (1993). Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors. J. Immunol. 151: 6577-6582.
28. Moritz, D., Wels, W., Mattern, F., and Groner, B. (1994). Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc. Natl. Acad. Sci. USA 91: 4318-4322.
29. Hwu, P., et al. (1995). In vivo antitumor activity of T cells redirected with chimeric antibody/T cell receptor genes. Cancer Res. 55: 3369-3373.
30. Brentjens, R. J., et al. (2003). Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat. Med. 3: 279-286.
31. Weijtens, M. E., Willemsen, R. A., Valerio, D., Stam, K., and Bolbuis, R. L. (1996). Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity. J. Immunol. 157: 836-843.
32. Gross, G., Levy, S., Levy, R., Waks, T., and Eshhar, Z. (1995). Chimeric T-cell receptors specific to a B-lymphoma idiotype: a model for tumor immunotherapy. Biochem. Soc. Trans. 23: 1079-1082.
33. + malignancy. Biol. Blood Marrow Transplant. 4: 75-83.
34. Jensen, M. C., et al. (2000). Human T lymphocyte genetic modification with naked DNA. Mol. Ther. 1: 49-55.
35. Jensen, M. C., Cooper, L., Wu, A. M., Forman, S. J., and Raubitschek, A. (2000). Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy. Cytotherapy 5: 131-138.
36. Schultze, J. L., Seamon, M. J., Michalak, S., Gribben, J. G., and Nadler, L. M. (1997). Autologous tumor infiltrating T cells cytotoxic for follicular lymphoma cells can be expanded in vitro. Blood 89: 3806-3816.
37. + T cells from tumor-invaded and tumor-free lymph nodes of melanoma patients: role of common gamma-chain cytokines. J. Immunol. 171: 2134-2141.